Last
Update:
March 07, 2018
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
|
Journal Papers, Abstracts, and Commentaries
| |
Effect of Offering Same-Day ART vs Usual Health Facility
Referral During Home-Based HIV Testing on Linkage to Care and Viral
Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized
Clinical Trial.
Labhardt ND, Ringera I, Lejone TI,
JAMA.
2018 Mar 6
Abstract
Development of an oral once-weekly drug delivery system for HIV
antiretroviral therapy.
Kirtane
AR, Abouzid O, Minahan D, et al
Nat Commun. 2018 Jan 9;9(1):2.
Abstract
FULL-TEXT ARTICLE
Platelet function and
cardiovascular risk in adult HIV-infected patients on HAART: a
protocol for a systematic review and meta-analysis.
Nkambule BB, Mkandla Z, Mutize T, Dludla PV.
BMJ Open. 2017 Dec
19;7(12):e019468
Paper
FULL-TEXT ARTICLE
Efficacy
and safety of switching from branded to generic antiretrovirals in
virologically suppressed HIV-infected patients.
Gianotti N, Poli A, Galli L, Franzin M, et al
PLoS One. 2017
Aug 1;12(8):e0182007.
Paper
A New HIV Paradigm: Dual Antiretroviral Regimens
as Maintenance Therapy.
Soriano V, Peña JM.
AIDS Rev.
2017 May 23;19(2)..
Abstract
FULL-TEXT
ARTICLE
Clinical decision tools are needed to identify HIV-positive patients at high
risk for poor outcomes after initiation of antiretroviral therapy.
McNairy
ML, Abrams EJ, Rabkin M, El-Sadr WM.
PLoS
Med. 2017 Apr 18
Paper
FULL-TEXT
ARTICLE
Current use of statins reduces risk of HIV rebound on suppressive
HAART.
Drechsler H, Ayers C,
Cutrell J, et al
PLoS One. 2017 Mar 1;12(3):e0172175.
Paper
A HAART-Breaking Review of Alternative Antiretroviral Administration:
Practical Considerations with Crushing and Enteral Tube Scenarios.
Huesgen E, DeSear KE, Egelund EF,
et al
Pharmacotherapy.
2016 Sep 16.
Abstract
BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in
young people with chronic human immunodeficiency virus infection: an open,
randomised, parallel-group Phase II/III trial.
Butler K, Inshaw J, Ford D,
et al
Health Technol Assess.
2016 Jun;20(49):1-108.
Abstract
Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus
Infection.
Kalapila AG, Marrazzo J.
Med Clin North Am. 2016 Jul;100(4):927-950.
Abstract
Assessing the HIV Care Continuum in Latin America: progress in clinical
retention, cART use and viral suppression.
Rebeiro
PF, Cesar C, Shepherd BE,
et al
J Int AIDS Soc.
2016 Apr 8;19(1):20636.
Abstract
FULL-TEXT ARTICLE
Dual Therapy Treatment Strategies for the Management of Patients Infected with
HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced,
Virologically Suppressed Patients.
Baril JG, Angel JB, Gill MJ,
et al
PLoS One.
2016 Feb 5;11(2):e0148231.
Paper
Socioeconomic and clinical factors explaining the risk of unstructured
antiretroviral therapy interruptions among Kenyan adult patients.
Mûnene E, Ekman B.
AIDS Care. 2016 Feb 5:1-9.
Abstract
FULL-TEXT ARTICLE
Choice of
antiretroviral drugs for continued treatment scale-up in a public health
approach: what more do we need to know?
Vitoria M, Hill AM, Ford NP,
et al
J Int AIDS Soc. 2016
Feb 2;19(1):20504.
Paper
Lipid-lowering therapy in HIV-infected patients: relationship with
antiretroviral agents and impact of substance-related disorders.
Bednasz C, Luque AE, Zingman BS, et al
Curr Vasc Pharmacol. 2016
Jan 6.
Abstract
Reducing Viral Load Measurements to Once a Year in Patients on Stable,
Virologically Suppressive Cart Regimen: Findings from the Australian HIV
Observational Database.
Rafiee M, Kariminia A, Wright S,
et alJ
AIDS Clin Res. 2014 Dec;5(12).
Abstract
FULL-TEXT ARTICLE
Neurological Response to cART vs. cART plus Integrase Inhibitor and
CCR5 Antagonist Initiated during Acute HIV.
Valcour VG, Spudich SS, Sailasuta N, et al
PLoS One.
2015 Nov 10;10(11):e0142600.
Paper
|
Computer-Aided Optimization of Combined Anti-Retroviral
Therapy for HIV: New Drugs, New Drug Targets and Drug Resistance.
Zazzi M, Cozzi-Lepri A, Prosperi MC.
Curr HIV Res. 2015 Oct 28
Abstract
No evidence of posttreatment control after early initiation
of antiretroviral therapy.
Gianella S, Anderson CM, Richman DD, et
al
AIDS. 2015 Oct
23;29(16):2093-2097.
Abstract
Improving care for patients on antiretroviral therapy through a gap analysis
framework.[Uganda]
Massoud MR, Shakir F, Livesley N, et
al
AIDS. 2015 Jul;29 Suppl
2:S187-S194.
Abstract
Four days a week or less on appropriate
anti-HIV drug combinations provided long-term optimal
maintenance in 94 patients: the ICCARRE project.
Leibowitch J, Mathez D, de Truchis P, et al
FASEB J.
2015 Apr 1
Abstract
FULL-TEXT PDF ARTICLE
Outcomes of second-line combination antiretroviral therapy
for HIV-infected patients: a cohort study from Rio de
Janeiro, Brazil
Cardoso S, Luz P, Velasque L, et al
BMC Infect Dis. 2014 Dec
19;14(1):699.
Paper
FULL-TEXT ARTICLE
A Novel Acute Retroviral Syndrome Severity Score Predicts
the Key Surrogate Markers for HIV-1 Disease Progression.
Braun DL, Kouyos R, Oberle C, et al
PLoS One.
2014 Dec 9;9(12):e114111.
Paper
Preserving HIV-specific T cell responses:
does timing of antiretroviral therapy help?
Macatangay BJ, Rinaldo CR.
Curr Opin HIV AIDS.
2014 Nov 11
Abstract
Influence of the Timing of Antiretroviral Therapy on the
Potential for Normalization of Immune Status in Human Immunodeficiency Virus
1-Infected Individuals.
Okulicz JF, Le TD, Agan BK, et al
JAMA Intern Med. 2014 Nov 24
Abstract
The importance of viral blips and duration of therapy
initiated in primary infection in maintaining viral control after stopping
cART.
Fidler S, Olson A, Fox J, Phillips A, et al
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):19820
Abstract
FULL-TEXT ARTICLE
Use of third line antiretroviral therapy in Latin America.
Cesar C, Shepherd BE, Jenkins CA,
PLoS
One. 2014 Sep
15;9(9):e106887.
Paper
FULL-TEXT
ARTICLE
Maximizing the benefits of antiretroviral
therapy for key affected populations.
Grubb IR, Beckham SW, Kazatchkine M, et al
J Int AIDS Soc.
2014 Jul 18;17(1):19320
Paper
Assessment of Second-Line Antiretroviral Regimens for HIV
Therapy in Africa.
Paton NI, Kityo C, Hoppe A, et al
N Engl J Med. 2014 Jul 17;371(3):234-47
Abstract
FULL-TEXT ARTICLE
The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in
Patients with Advanced AIDS Who Manifest No Virologic or Immunologic
Benefit.
Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, et al
PLoS One. 2013 Nov 15;8(11):e78676.
Paper
Legal, ethical, and economic implications of breaking down
once-daily fixed-dose antiretroviral combinations into their single
components for cost reduction.
Ramiro MA, Llibre JM.
Enferm Infecc Microbiol Clin. 2013 Oct 16.
Abstract
Beyond first-line HIV treatment regimens: the current state
of antiretroviral regimens, viral load monitoring, and resistance testing in
resource-limited settings.
Kumarasamy N, Krishnan S.
Curr Opin HIV AIDS. 2013 Oct
4.
Abstract
Treatment optimization: an outline for future success.
Flexner C, Plumley B, Brown Ripin DH.
Curr Opin HIV AIDS.
2013 Oct 4..
Abstract
Effective treatment of a highly active antiretroviral regimen
through jejunostomy.
Florit-Sureda M, Giner-Soriano M, et al
J Chemother.
2013 Sep 27..
Abstract
Immune activation and HIV persistence: implications for curative
approaches to HIV infection.
Klatt NR, Chomont N, Douek DC, Deeks SG.|
Immunol Rev.
2013 Jul;254(1):326-42
Abstract
FULL-TEXT PDF ARTICLE
Management of HIV infection after triple class failure.
Cossarini F, Spagnuolo V, Gianotti N, et al
New Microbiol.
2013 Jan;36(1):23-39.
Paper |
Individualization
of antiretroviral therapy.
Pavlos R, Phillips EJ
Pharmgenomics Pers Med.
2012;5:1-17. .
Abstract |
No advantage of quadruple or triple-class
antiretroviral therapy as initial treatment in patients
with very
high viraemia.
Grijsen ML, Holman R, Gras L, et al
Antivir Ther.
2012 Aug 20..
Abstract
Neurocognitive Impact of Antiretroviral Treatment: Thinking
Long-Term.
McPhail ME, Robertson KR.
Curr HIV/AIDS Rep.
2011 Aug 12.
Abstract
Protective role of antiretroviral treatment in the
impairment of renal function in a
cohort of human immunodeficiency virus patients.
Mérida L, De la Torre J, Olalla J,
et al
Med Clin (Barc).
2011 Mar 10.
Abstract
High Dose Atorvastatin Decreases Cellular Markers of Immune Activation
without Affecting
HIV-1 RNA Levels: Results of a Double-Blind Randomized Placebo
Controlled Clinical Trial.
Ganesan A, Crum-Cianflone N, Higgins J, et al
J Infect Dis. 2011
Feb 15
Abstract
The impact of HIV drug resistance testing on
changes to treatment.
Bansi L, Smith C, Phillips A,
et al
AIDS.
2011 Feb
Abstract
FULL-TEXT PDF
ARTICLE
Antiretroviral Therapy Optimisation without Genotype
Resistance Testing: A Perspective on Treatment History
Based Models.
Prosperi MC, Rosen-Zvi M, Altmann A, et al
PLoS One.
2010 Oct 29;5(10):e13753
Paper |
Role of fixed-dose combinations of antiretrovirals in HIV-1
therapy.
Llibre JM, Antela A, Arribas JR, et al|
Enferm Infecc Microbiol Clin.
2010 Sep 29
Abstract |
The prognosis of patients with dissociated
virological and immunological responses
to HAART.
Jevtović D, Salemović D, Ranin J, et al
Biomed Pharmacother.
2010 Sep 20.
Abstract |
Optimal antiretroviral therapy: HIV-1 treatment
strategies to avoid and overcome
drug resistance.
Grant PM, Zolopa AR.
Curr Opin Investig Drugs.
2010 Aug;11(8):901-10
Abstract |
Doctor-patient concordance during HIV treatment
switching decision-making.
Clucas C, Harding R, Lampe F,
et al
HIV Med.
2010 Jun 17.
Abstract |
Impact of antiretroviral treatment on (13)C-methionine metabolism
as a marker of
hepatic mitochondrial function: a longitudinal study.
Banasch M, Frank J, Serova K, et al
HIV Med. 2010 May
23.
Abstract |
Transient Lowering of the Viral Set Point After Temporary
Antiretroviral
Therapy of Primary HIV Type 1 Infection.
Steingrover R, Garcia EF, van Valkengoed IG,
et al
AIDS Res Hum Retroviruses.
2010 Apr 8
Abstract |
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected
patients
during first-line highly active antiretroviral therapy.
Castagna A, Galli L, Torti C, et al
Antivir Ther.
2010;15(2):165-75.
Abstract |
Therapy for persistent HIV.
Keedy KS, Margolis DM.
Trends Pharmacol Sci.
2010 Mar 4
Abstract |
|
|
|
|
|
Conference Reports, Abstracts, and
Posters
|
| |
|
Journal Papers, Abstracts, and Commentaries
|
| |
Lower Pill Burden and Once-daily Dosing Antiretroviral Treatment
Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials.
Nachega JB, Parienti JJ, Uthman OA, et al
Clin Infect Dis. 2014 Jan
22.
Abstract
A survey of patients' willingness to switch from a single-tablet
regimen to 2 pills once a day as a cost-saving strategy.
Tan J, Sonecha S, Mandalia S, Nelson M.
J Int AIDS Soc. 2012 Nov 11;15(6):18388
Abstract
Once-daily single-tablet regimens: a long and winding road to
excellence in antiretroviral treatment.
Llibre JM, Clotet B.
AIDS Rev. 2012 Jul;14(3):168-78.
Abstract
One-pill once-a-day HAART: a simplification strategy that improves adherence
and quality of life of HIV-infected subjects.
Airoldi M, Zaccarelli M, Bisi L, et al
Patient Prefer Adherence. 2010 May 13;4:115-25.
Abstract |
|
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
| |
Efficacy and safety of contemporary dual-drug
antiretroviral regimens as first-line treatment or as a simplification
strategy: a systematic review and meta-analysis.
Achhra AC, Mwasakifwa
G, Amin J, Boyd MA
Lancet HIV. 2016
Aug;3(8):e351-60
Abstract
Monotherapy with boosted PIs as an ART simplification
strategy in clinical practice
Santos JR, Llibre JM, Berrio-Galan D, et al
J Antimicrob Chemother. 2014 Dec
18.
Abstract
Nuke-sparing regimens as a main simplification strategy
and high level of toxicity resolution after antiretroviral switch: the
SWITCHART Study.
Carrero-Gras A, Antela A, Muñoz-Rodríguez J, Díaz-Menéndez M, et
al
J Int AIDS Soc.
2014 Nov 2;17(4(Suppl 3)):19819.
Abstract
Simplification of antiretroviral therapy: a necessary
step in the public health response to HIV/AIDS in resource-limited
settings.
Vitoria M, Ford N, Doherty M, Flexner C.
Antivir Ther. 2014;19(Suppl 3):31-37
Abstract
Optimization and simplification of antiretroviral therapy
for adults and children.
Ford N, Flexner
C, Vella S, et al
Curr Opin HIV AIDS. 2013 Oct 4
Abstract
Simplification of antiretroviral therapy: a good choice for our patients and
the sustainability of our health care system.
González Rivas L, Sánchez Gómez E,
et
al
Farm Hosp. 2011 Oct 19.
Abstract
Treatment simplification in HIV-infected adults as a strategy to
prevent toxicity,
improve adherence, quality of life and decrease healthcare costs.
Nachega JB, Mugavero MJ, Zeier M,
et al
Patient Prefer Adherence.
2011;5:357-6
Abstract
One-pill once-a-day HAART: a simplification strategy that improves adherence
and quality of life of HIV-infected subjects.
Airoldi M, Zaccarelli M, Bisi L, et al
Patient Prefer Adherence.
2010 May 13;4:115-25.
Abstract |
|
|
|
HAART
Main Page
